Increased cellular immune responses and CD4+ T-cell proliferation correlate with reduced plasma viral load in SIV challenged recombinant simian varicella virus - Simian immunodeficiency virus (rSVV-SIV) vaccinated rhesus macaques

Virology Journal

Volumn 9, Issue , 2012, Pages

  Pahar, Bapi ^a   Gray, Wayne L ^b   Phelps, Kimberly ^c   Didier, Elizabeth S ^a   Deharo, Eileen ^a   Marx, Preston A ^a   Traina Dorge, Vicki L ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Cytokine; Memory; Proliferation; Simian immunodeficiency virus (SIV); Simian varicella virus (SVV); T cells; Vaccine

Indexed keywords

GAG PROTEIN; HERPESVIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; INFECTION CONTROL; LYMPHOCYTE PROLIFERATION; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN VARICELLA VIRUS; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRAL GENE DELIVERY SYSTEM; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; MACACA MULATTA; PLASMA; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VARICELLOVIRUS; VIRAL LOAD; VIREMIA;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 9; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84864819487     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-160     Document Type: Article

References (22)

1. Control of viremia and maintenance of intestinal CD4(+) memory T-cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, Das A, Ling B, Montefiori DC, Veazey RS, Virology 2009 387 273 284
2. HIV vaccine design: insights from live attenuated SIV vaccines. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC, Nat Immunol 2006 7 19 23 (Pubitemid 41823864)
3. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR, et al. J Med Primatol 1992 21 99 107
4. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. N Engl J Med 2009 361 2209 2220
5. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, Sanmiguel A, Seaman MS, Ferrari G, et al. Nature 2012 482 89 93
6. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al. Nature 2011 473 523 527
7. Development of recombinant varicella-zoster virus vaccines. Arvin AM, Mallory S, Moffat JF, Contrib Microbiol 1999 3 193 200
8. Simian varicella: a model for human varicella-zoster virus infections. Gray WL, Rev Med Virol 2004 14 363 381 (Pubitemid 39487679)
9. Simian varicella in old world monkeys. Gray WL, Comp Med 2008 58 22 30 (Pubitemid 351413454)
10. Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Traina-Dorge V, Pahar B, Marx P, Kissinger P, Montefiori D, Ou Y, Gray WL, Vaccine 2010 28 6483 6490
11. Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Ou Y, Traina-Dorge V, Davis KA, Gray WL, Virology 2007 364 291 300 (Pubitemid 46881085)
12. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K, Vaccine 2006 24 6839 6849 (Pubitemid 46107190)
13. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F, Hamann D, Blood 2000 95 249 255 (Pubitemid 30017249)
14. Differential dynamics of CD4(+) and CD8(+) T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection. Kaur A, Hale CL, Ramanujan S, Jain RK, Johnson RP, J Virol 2000 74 8413 8424 (Pubitemid 30666692)
15. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, et al. J Infect Dis 1999 179 859 870 (Pubitemid 29159331)
16. Virus-specific T-cell responses in macaques acutely infected with SHIV(sf162p3). Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS, Virology 2007 363 36 47 (Pubitemid 46678163)
17. HIV-1-specific interleukin-21+ CD4+ T-cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T-cell function. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, et al. J Virol 2011 85 733 741
18. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T-cells. Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, Rosenberg ES, J Virol 2004 78 8844 8851 (Pubitemid 39025149)
19. Cytolytic CD4(+) T-cells in viral immunity. Soghoian DZ, Streeck H, Expert Rev Vaccines 2010 9 1453 1463
20. Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Harari A, Petitpierre S, Vallelian F, Pantaleo G, Blood 2004 103 966 972 (Pubitemid 38129558)
21. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD, Science 1997 278 1447 1450 (Pubitemid 27509814)
22. HIV preferentially infects HIV-specific CD4+ T-cells. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, et al. Nature 2002 417 95 98 (Pubitemid 34498823)